Drug
Crysvita Treatment
Crysvita Treatment: highest development phase Post-Market, developed by Ultragenyx Pharmaceutical. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Ultragenyx Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| Crysvita (burosumab-twza) Treatment NCT04320316 | Post-Market | Epidermal Nevus Syndrome |
Latest
No recent events.
Follow Crysvita Treatment on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.